Original Research
The clinical pharmacology of hirudin - a new anti-coagulant
Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie | Vol 11, No 2 | a526 |
DOI: https://doi.org/10.4102/satnt.v11i2.526
| © 1992 B. H. Meyer, F. O. Muller, H. G. Luus, N. de la Rey
| This work is licensed under CC Attribution 4.0
Submitted: 09 July 1992 | Published: 09 July 1992
Submitted: 09 July 1992 | Published: 09 July 1992
About the author(s)
B. H. Meyer,, South AfricaF. O. Muller,, South Africa
H. G. Luus,, South Africa
N. de la Rey,, South Africa
Full Text:
PDF (161KB)Abstract
Increasing doses of 0,05, 0,1, 0,15 and 0,2 mg/kg of rDNA hirudin, a new anti-coagulant, were given subcutaneously to 20 volunteers (5 per dose) in order to investigate the tolerance and pharmacokinetics of the compound and its effects on coagulation. Hirudin was tolerated very well, the elimination half-life after subcutaneous injections is about 2 hours, about 40% of a given dose is excreted through the kidneys, and an excellent linear relationship was found between the area under the plasma concentration time curve and the dose. Hirudin increased partial thromboplastin time in a dose-related fashion.
Keywords
No related keywords in the metadata.
Metrics
Total abstract views: 1893Total article views: 1526
Reader Comments
Before posting a comment, read our privacy policy.Post a comment (login required)